tert-butyl 2,5-dihydropyrrole | 60138-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 英文名称: tert-butyl 2,5-dihydropyrrole
• 英文别名: N-tert.-Butyl-Δ³-pyrrolin；1-tert-butyl-2,5-dihydro-pyrrole；1-Tert-butyl-2,5-dihydropyrrole
• CAS: 60138-51-4
• 化学式: C₈H₁₅N
• 分子量: 125.214
• InChiKey: MLEGUJVPSFAYQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  tert-butyl 2,5-dihydropyrrole 在 四氧化锇 、 碘苯二乙酸 、 N-甲基吗啉氧化物 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 37.33h， 生成 tert-butyl bis(2-hydroxybut-3-en-1-yl)carbamate
  参考文献：
  名称：

  An Efficient Synthesis of Bridged Heterocycles from an Ir(I) Bis-Amination/Ring-Closing Metathesis Sequence

  摘要：

  The amination of bis-allylic imidates using an Iridium(I) catalyst leads to the efficient formation of 2,6-divinyl heterocycles. Careful screening of amines, solvents, and conditions has led to the discovery of a system that favors formation of the desired cis products with synthetically useful levels of diastereoselectivity, and these results are further explained by computer based transition state energy calculations. Exposure of the heterocycles to ring-closing metathesis catalysts leads to the desired bridged heterocyclic systems.

  DOI：

  10.1021/ol302108m

文献信息

• NEPRILYSIN INHIBITORS
  申请人：SMITH Cameron

  公开号：US20120157386A1

  公开（公告）日：2012-06-21

  In one aspect, the invention relates to compounds having the formula: where R 1 -R 6 , a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

  在一方面，本发明涉及具有以下公式的化合物： 其中R1-R6、a、b和X如说明书所述，或其药用可接受的盐。这些化合物具有中性粒细胞弹性蛋白酶抑制活性。在另一方面，本发明涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF
  申请人：Nanjing TransThera Biosciences Co. Ltd.

  公开号：US20190209564A1

  公开（公告）日：2019-07-11

  Provided are an irreversible inhibitor of a fibroblast growth factor receptor (FGFR) as indicated by formula I, a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical preparation, a pharmaceutical composition and an application thereof. R 1 , R 2 , R 3 , R 4 , ring A, Ar, ring B and warhead are as defined in the specification. The compound has high-efficiency and high-selectivity inhibition of a fibroblast growth factor receptor and can be applied to treatment of abnormal FGF/FGFR-mediated diseases, in particular the treatment of cancers.

  提供了一种不可逆的成纤维细胞生长因子受体（FGFR）抑制剂，如式I所示，以及其药学上可接受的盐、立体异构体、药物制剂、药物组合物及其应用。R1、R2、R3、R4、环A、Ar、环B和弹头如说明书中所定义。该化合物对成纤维细胞生长因子受体具有高效和高选择性的抑制作用，可用于治疗异常FGF/FGFR介导的疾病，特别是癌症的治疗。
• FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF
  申请人：SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

  公开号：US20160214994A1

  公开（公告）日：2016-07-28

  Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applications of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.

  揭示了一种融合嘧啶化合物，其中间体，制备方法以及其组成和应用。本发明提供了一种如式I所示的融合嘧啶化合物，该化合物的药用可接受盐，水合物，溶剂合物，以及光学异构体或前药。本发明还提供了应用式I所示的融合嘧啶化合物，药用可接受盐，水合物，溶剂合物，以及该化合物的光学异构体或前药在制备用于治疗和/或预防激酶相关疾病的药物中。本发明的融合嘧啶化合物I是一种高效的PI3激酶抑制剂，可用于制备用于预防和/或治疗细胞增殖性疾病，如癌症，感染，炎症和自身免疫疾病的药物。
• HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
  申请人：Amberg Wilhelm

  公开号：US20100041698A1

  公开（公告）日：2010-02-18

  The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.

  该发明涉及一般式（I）的化合物，其相应的对映体、异构体和/或互变异构体形式，以及其药学上可接受的盐和所述化合物的前药。该发明还涉及将所述化合物用作5-HT5受体的结合伙伴，用于治疗受5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状和功能障碍。
• PROLYL HYDROXYLASE INHIBITORS
  申请人：Gardner Joseph H.

  公开号：US20110110961A1

  公开（公告）日：2011-05-12

  Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1α), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.

  本文披露了一种可以稳定缺氧诱导因子-1α（HIF-1α）和缺氧诱导因子-2（HIF-2）的脯氨酸羟化酶抑制剂。本文还披露了包含所述化合物的一种或多种药物组合物。此外，还披露了一种用于刺激哺乳动物细胞免疫应答的方法，例如增加吞噬作用，延长吞噬细胞（包括角质细胞、中性粒细胞等）的寿命。因此，所披露的化合物提供了治疗与机体免疫应答相关疾病的方法。